All News

Two separate studies highlighted how high drug costs and requirements for prior authorization can hinder access to cancer treatment and affect outcomes.

Anifrolumab (AstraZeneca) demonstrated a statistically significant and clinically meaningful reduction in disease activity based on composite lupus assessment.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Pharmacists can assist with advising patients who present with quality concerns to use CBD products that provide certificates of analyses, and catch significant drug interactions before they occur.

Voxelotor (Global Blood Therapeutics) is being developed for patients with sickle cell disease.

Oncologists suggest that substituting nab-paclitaxel instead of paclitaxel prior to surgery may lead to reduced risk of disease recurrence for certain women with breast cancer.

Top news of the day from across the health care landscape.

These funds are earmarked for the expansion of access to treatment and to support near real-time data on drug overdoses.

A federal court has ordered 2 Tennessee-based companies with the same owner to stop disstributing drugs, dietary supplements, and devices until they are found to be in compliance with the Federal Food, Drug, and Cosmetic (FD&C) Act and other requirements.

Health system specialty pharmacies are creating a more integrated care structure for complex patients on specialty drug regimens.

Building on the current understanding of spihingosine 1-phosphate levels in regulating T cell function, researchers found that the inhibition of the lipid can lead to more effective uses of immunotherapy in cancer therapy.

Top news of the day from across the health care landscape.

It is important to have an emergency plan that helps protect pharmacists, pharmacies, and their patients when these catastrophes hit, as well as the aftermath.

The gel product, which was first approved by the FDA in 2013, is intended for cheek augmentation to correct age-related volume deficit in the mid-face in adults over age 21 years.

The study findings suggest that, while the link between chronic lymphocytic leukemia and melanoma had been known, the rate at which the link occurs is higher than expected.

Novel treatment approach combines a new immunotherapy with stem cell transplantation.

Top news of the day from across the health care landscape.

What is causing the oliguria in this normally healthy young man with a history of acne and a current sinus infection?

Specialty pharmacists play an important role in the selection of immunoglobulin G products and optimizing therapy for patients.

The antivaccination movement has been a driving force in the global measles outbreaks, and dissemination of inaccurate information has contributed to the growing problem.

In recent years, health care professionals have been seeing a surge in adverse effects associated with long-term use of antibiotics, as well as abuse, not only in the United States, but around the world.

As the industry moves toward a more patient-centric model, pharmacy schools like Touro are implementing programs to ensure their students are prepared for every aspect of their career—including physical exams.

Recently published in Science Daily, the study was based on the investigating team’s analysis of more than 12 million reports from the FDA Adverse Effect Reporting System (FAERS) and Adverse Event Reporting System (AERS) databases.

A randomized clinical trial found that among patients with psychotic depression in remission, continuing sertraline plus olanzapine reduced the risk of relapse over 36 weeks when compared with sertraline plus a placebo.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.